← FDA DRUG APPROVALS

FDA ANDA · ANDA200363

QUETIAPINE FUMARATE

Sponsor: TORRENT PHARMS LTD

APPLICATION
ANDA200363
TYPE
ANDA
ORIGINAL APPROVAL
2012-03-27
LATEST ACTION
2015-11-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

QUETIAPINE FUMARATEDiscontinued
QUETIAPINE FUMARATE EQ 300MG BASE · TABLET · ORAL
QUETIAPINE FUMARATEDiscontinued
QUETIAPINE FUMARATE EQ 100MG BASE · TABLET · ORAL
QUETIAPINE FUMARATEDiscontinued
QUETIAPINE FUMARATE EQ 25MG BASE · TABLET · ORAL
QUETIAPINE FUMARATEDiscontinued
QUETIAPINE FUMARATE EQ 400MG BASE · TABLET · ORAL
QUETIAPINE FUMARATEDiscontinued
QUETIAPINE FUMARATE EQ 200MG BASE · TABLET · ORAL
QUETIAPINE FUMARATEDiscontinued
QUETIAPINE FUMARATE EQ 50MG BASE · TABLET · ORAL

Approval history

2015-11-24Labeling · Supplement 3 · standardAP
2012-03-27Not Applicable · Original — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →